Page last updated: 2024-12-10

7-benzylidenenaltrexone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-benzylidenenaltrexone: structure given in first source; a highly selective delta1-opioid receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438353
CHEMBL ID101519
CHEBI ID125500
SCHEMBL ID15354616
MeSH IDM0207731
PubMed CID5310988
CHEMBL ID252172
CHEBI ID138855
SCHEMBL ID1237777
MeSH IDM0207731

Synonyms (28)

Synonym
(1s,5r,13r,15z,17s)-4-(cyclopropylmethyl)-10,17-dihydroxy-15-(phenylmethylidene)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18)-trien-14-one
gtpl1634
bntx-7
morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-7-(phenylmethylene)-, (5alpha)-
CHEBI:125500
CHEMBL101519 ,
bdbm50450986
SCHEMBL15354616
(4r,4as,6z,7ar,12bs)-6-benzylidene-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Q27075416
PDSP2_001550
153611-34-8
(e)-7-benzylidenenaltrexone
morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-7-(phenylmethylene)-, (5alpha,7e)- (9ci)
7(e)-benzylidenenaltrexone
morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-7-(phenylmethylene)-, (5alpha,7e)-
7-benzylidine-7-dehydronaltrexone
7-benzylidenenaltrexone
CHEBI:138855
bntx
CHEMBL252172
129468-28-6
C20167
BRD-K18722736-001-01-3
SCHEMBL1237777
bdbm50454798
(4r,4as,6e,7ar,12bs)-6-benzylidene-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
SDCCGSBI-0633734.P001

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" ICR mice were used to generate full antagonist dose-response curves for naloxone, naltrexone, nalbuphine, and 6beta-naltrexol in blocking acute antinociceptive effects of morphine and precipitating opioid withdrawal in models of physical dependence."( In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Bhamidipati, CM; Bilsky, EJ; Blair, JR; Lowery, JJ; Paolino, RM; Raehal, KM; Sadée, W; Wang, D, 2005
)
0.33
" Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase."( Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens.
Chung, HK; Lamb, K; Lin, MZ; Plemper, RK; Weisshaar, M; Yan, D, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenanthrenesAny benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorRattus norvegicus (Norway rat)Ki0.00230.00000.60689.2330AID147818; AID56441
Mu-type opioid receptorHomo sapiens (human)Ki0.00190.00000.419710.0000AID224713
Delta-type opioid receptorHomo sapiens (human)Ki0.00270.00000.59789.9300AID147838; AID149906
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.03390.00000.20186.4240AID147838; AID148742; AID149277
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.03300.00000.27869.0000AID148038
Delta-type opioid receptorRattus norvegicus (Norway rat)Ki0.00320.00000.60689.2330AID147818; AID56441
Mu-type opioid receptorHomo sapiens (human)Ki0.01160.00000.419710.0000AID1292339; AID1461557; AID224713
Delta-type opioid receptorHomo sapiens (human)Ki0.00560.00000.59789.9300AID1292340; AID1461558; AID147838; AID149906
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.02130.00000.20186.4240AID147838; AID148742; AID149277
Kappa-type opioid receptorHomo sapiens (human)Ki0.03060.00000.362410.0000AID1292341; AID1461559
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.02600.00000.27869.0000AID148038
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorMus musculus (house mouse)Ke0.02400.00010.14726.1080AID148953
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ke0.03370.00000.03891.1570AID148953; AID77783
Delta-type opioid receptorMus musculus (house mouse)Ke0.00290.00010.14726.1080AID148953
Delta-type opioid receptorRattus norvegicus (Norway rat)Activity0.00010.00000.11931.2200AID310939
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ke0.03530.00000.03891.1570AID148953; AID77783
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ke0.00830.00000.01590.0430AID141500
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (89)

Assay IDTitleYearJournalArticle
AID149906Binding affinity was determined in a crude membrane preparation from guinea pig brain by displacement of [3H]DPDPE from Opioid receptor delta 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
(E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays.
AID148699Inhibition of ethylketazocine binding to Opioid receptor kappa 1 of guinea pig ileal longitudinal muscle1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID148295Antagonism of antinociceptive effect of U-50,488 against Opioid receptor kappa 1 in male ICR mice at a sc dose of 16 umol/kg1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID229269Ratio of IC50 in presence of antagonist to that of control IC50 value in delta opioid receptor using DADLE ligand in mouse vas deferens1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID148038Binding affinity was determined in a crude membrane preparation from guinea pig brain by displacement of [3H]DAMGO from Opioid receptor mu 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
(E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays.
AID77783Tested for antagonist potency against kappa receptor using ethylketazocine ligand in guinea pig ileal longitudinal muscle at 100 nM concentration1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID235342Selectivity ratio against mu opioid receptor to that of delta opioid receptor1999Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3
The LMC delta opioid recognition pharmacophore: comparison of SNC80 and oxymorphindole.
AID148742Tested for binding activity against kappa opioid receptor using [3H]U-69593 ligand1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID141501Tested for antagonist potency against mu opioid receptor using morphine ligand in guinea pig ileal longitudinal muscle at 100 nM concentration; cannot be calculated1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID149877Inhibition of morphine binding to Opioid receptor mu 1 of guinea pig ileal longitudinal muscle1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID149277Binding affinity was determined in a crude membrane preparation from guinea pig brain by displacement of [3H]U-69593 from Opioid receptor kappa 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
(E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays.
AID151131Antagonism of antinociceptive effect of morphine against Opioid receptor mu 1 in male ICR mice at a sc dose of 1.25 umol/kg1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID151132Antagonism of antinociceptive effect of morphine against Opioid receptor mu 1 in male ICR mice at a sc dose of 16 umol/kg1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID148297Antagonism of antinociceptive effect of U-50,488 against kOpioid receptor kappa 1 in male ICR mice at a sc dose of 1.25 umol/kg1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID232959Relative affinity for delta and kappa receptors1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID229268Ratio of IC50 in presence of antagonist to that of control IC50 value against mu opioid receptor using morphine ligand in guinea pig ileal longitudinal muscle1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID56145Antagonism of antinociceptive effect of DPDPE against delta 1 opioid receptor in male ICR mice at a sc dose of 16 umol/kg1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID148953Tested for antagonist potency against delta opioid receptor using DADLE ligand in mouse vas deferens at 100 nM concentration1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID147838Tested for binding activity against Opioid receptor delta 2 using [3H]DSLET ligand1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID232960Relative affinity for delta and mu receptors1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID148782Inhibition of DADLE binding to Opioid receptor delta 1 of mouse vas deferens1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID229267Ratio of IC50 in presence of antagonist to that of control IC50 value against kappa opioid receptor using ethylketazocine ligand in guinea pig ileal longitudinal muscle1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID224713Tested for binding activity against mu opioid receptor using [3H]DAMGO ligand1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID56144Antagonism of antinociceptive effect of DPDPE against delta 1 opioid receptor in male ICR mice at a sc dose of 1.25 umol/kg1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID233909Selectivity ratio measured in terms of delta opioid receptor to the mu opioid receptor1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
(E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays.
AID147818Tested for binding activity against Opioid receptor delta 1 using [3H]DPDPE ligand1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID56277Antagonism of antinociceptive effect of DSLET against delta 2 opioid receptor in male ICR mice at a sc dose of 16 umol/kg1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID56441Binding affinity evaluated by inhibition of binding of [3H]DADLE to delta opioid receptor of rat brain1999Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3
The LMC delta opioid recognition pharmacophore: comparison of SNC80 and oxymorphindole.
AID230637Ke (kappa/delta) ratio of the compound1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID56147Antagonism of antinociceptive effect of DSLET against delta 2 opioid receptor in male ICR mice at a sc dose of 1.25 umol/kg1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
AID1346406Rat delta receptor (Opioid receptors)1999British journal of pharmacology, Oct, Volume: 128, Issue:3
Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.
AID1346361Human delta receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346373Mouse delta receptor (Opioid receptors)1994Molecular pharmacology, Feb, Volume: 45, Issue:2
Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.
AID1346329Human kappa receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346364Human mu receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID148742Tested for binding activity against kappa opioid receptor using [3H]U-69593 ligand1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID230637Ke (kappa/delta) ratio of the compound1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID1292339Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
AID1461560Antimicrobial activity against Tritrichomonas mobilensis after 48 hrs by neutral red staining based invert microscopic analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.
AID128803Antagonism of kappa1 opioid agonist (U-50,488)-induced antinociception upon intrathecal administration in mice at a dose of 25 pmol2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.
AID1292340Displacement of [3H]DPDPE from human delta opioid receptor expressed in CHO cell membranes2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
AID233443Selectivity ratio measured as the delta IC50 to that of mu IC50 values.1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Pyrrolomorphinans as delta opioid receptor antagonists. The role of steric hindrance in conferring selectivity.
AID148830Activity against Opioid receptor kappa 1 on electrically stimulated guinea pig ileum using ethylketazocine as the standard agonist.1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Pyrrolomorphinans as delta opioid receptor antagonists. The role of steric hindrance in conferring selectivity.
AID673396Inhibition of Plasmodium chabaudi glutathione reductase assessed as residual reduced glutathione level after 30 mins in absence of glutathione S-transferase2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Investigation of 7-benzylidenenaltrexone derivatives as resistance reverser for chloroquine-resistant Plasmodium chabaudi.
AID148038Binding affinity was determined in a crude membrane preparation from guinea pig brain by displacement of [3H]DAMGO from Opioid receptor mu 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
(E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays.
AID310939Displacement of [3H]naltrindole from rat delta opioid receptor expressed in C6 cells2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.
AID77783Tested for antagonist potency against kappa receptor using ethylketazocine ligand in guinea pig ileal longitudinal muscle at 100 nM concentration1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID147818Tested for binding activity against Opioid receptor delta 1 using [3H]DPDPE ligand1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID1461556Antimicrobial activity against Trichomonas vaginalis after 48 hrs by neutral red staining based invert microscopic analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.
AID149906Binding affinity was determined in a crude membrane preparation from guinea pig brain by displacement of [3H]DPDPE from Opioid receptor delta 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
(E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays.
AID229267Ratio of IC50 in presence of antagonist to that of control IC50 value against kappa opioid receptor using ethylketazocine ligand in guinea pig ileal longitudinal muscle1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID673397Inhibition of Plasmodium chabaudi glutathione reductase assessed as residual reduced glutathione level after 30 mins in presence of glutathione S-transferase2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Investigation of 7-benzylidenenaltrexone derivatives as resistance reverser for chloroquine-resistant Plasmodium chabaudi.
AID609328Antimalarial activity against chloroquine-resistant Plasmodium chabaudi infected in mouse assessed as parasitemia at 10 mg/kg, po administered for 3 consecutive days2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Opioid δ₁ receptor antagonist 7-benzylidenenaltrexone as an effective resistance reverser for chloroquine-resistant Plasmodium chabaudi.
AID1461557Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.
AID233442Selectivity ratio measured as the delta IC50 to that of kappa IC50 values.1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Pyrrolomorphinans as delta opioid receptor antagonists. The role of steric hindrance in conferring selectivity.
AID1292341Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
AID128809Antagonism of kappa2 opioid agonist (bremazocine)-induced antinociception upon intrathecal administration in mice at a dose of 25 pmol2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.
AID1434285Selectivity ratio of Ki for displacement of [3H]U69593 from KOR in guinea pig brain membranes to Ki for displacement of [3H]DAMGO from MOR in guinea pig brain membranes2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
AID229268Ratio of IC50 in presence of antagonist to that of control IC50 value against mu opioid receptor using morphine ligand in guinea pig ileal longitudinal muscle1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID673399Antimalarial activity against chloroquine-resistant Plasmodium chabaudi infected in mouse assessed as reversal of chloroquine-resistance at 10 mg/kg, po administered 4 days after post infection2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Investigation of 7-benzylidenenaltrexone derivatives as resistance reverser for chloroquine-resistant Plasmodium chabaudi.
AID112538Compound was tested for its ability to antagonize the antinociceptive effect of DSLET (delta-2 opioid receptor agonist) in mice1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID1461559Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.
AID150002Activity against mu receptor on electrically stimulated guinea pig ileum using morphine as the standard agonist (Opioid receptor mu 1)1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Pyrrolomorphinans as delta opioid receptor antagonists. The role of steric hindrance in conferring selectivity.
AID233909Selectivity ratio measured in terms of delta opioid receptor to the mu opioid receptor1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
(E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays.
AID128675Antagonism of delta1 opioid agonist (DPDPE)-induced antinociception upon intrathecal administration in mice at a dose of 25 pmol2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.
AID112539Compound was tested for its ability to antagonize the antinociceptive effect of U-69,594 (kappa opioid receptor agonist) in mice1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID1292343Selectivity ratio of Ki for human kappa opioid receptor expressed in CHO cell membranes to Ki for human delta opioid receptor expressed in CHO cell membranes2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
AID56441Binding affinity evaluated by inhibition of binding of [3H]DADLE to delta opioid receptor of rat brain1999Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3
The LMC delta opioid recognition pharmacophore: comparison of SNC80 and oxymorphindole.
AID148795Activity against Opioid receptor delta 1 on electrically stimulated mouse vas deferens using DADLE as agonist1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Pyrrolomorphinans as delta opioid receptor antagonists. The role of steric hindrance in conferring selectivity.
AID1254732Antitrichomonal activity against Trichomonas vaginalis after 48 hrs by invert microscope analysis2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
Investigation of 7-benzylidenenaltrexone derivatives as a novel structural antitrichomonal lead compound.
AID149277Binding affinity was determined in a crude membrane preparation from guinea pig brain by displacement of [3H]U-69593 from Opioid receptor kappa 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
(E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays.
AID147838Tested for binding activity against Opioid receptor delta 2 using [3H]DSLET ligand1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID1434283Displacement of [3H]DPDPE from DOR in guinea pig brain membranes measured after 60 mins by scintillation counting method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
AID673398Inhibition of Plasmodium chabaudi glutathione reductase assessed as residual reduced glutathione level after 30 mins2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Investigation of 7-benzylidenenaltrexone derivatives as resistance reverser for chloroquine-resistant Plasmodium chabaudi.
AID112540Compound was tested for its ability to antagonize the antinociceptive effect of morphine (mu opioid receptor agonist) in mice1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID148953Tested for antagonist potency against delta opioid receptor using DADLE ligand in mouse vas deferens at 100 nM concentration1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID128681Antagonism of delta2 opioid agonist (deltorphin II)-induced antinociception upon intrathecal administration in mice at a dose of 25 pmol2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.
AID141500Tested for antagonist potency against mu opioid receptor using morphine ligand in guinea pig ileal longitudinal muscle at 100 nM concentration1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID230638Ke (mu/delta) ratio of the compound1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID1292342Selectivity ratio of Ki for human mu opioid receptor expressed in CHO cell membranes to Ki for human delta opioid receptor expressed in CHO cell membranes2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
AID1434286Selectivity ratio of Ki for displacement of [3H]DAMGO from MOR in guinea pig brain membranes to Ki for displacement of [3H]DPDPE from DOR in guinea pig brain membranes2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
AID112537Compound was tested for its ability to antagonize the antinociceptive effect of DPDPE (delta-1 opioid receptor agonist) in mice1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID224713Tested for binding activity against mu opioid receptor using [3H]DAMGO ligand1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
AID1434282Displacement of [3H]DAMGO from MOR in guinea pig brain membranes measured after 60 mins by scintillation counting method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
AID1434284Displacement of [3H]U69593 from KOR in guinea pig brain membranes measured after 60 mins by scintillation counting method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
AID1461558Displacement of [3H]DPDPE from human delta opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.
AID609329Reversal of chloroquine-resistance in Plasmodium chabaudi infected in mouse at 10 mg/kg, po coadministered with chloroquine 3 mg/kg, iv administered for 3 consecutive days measured on day 42011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Opioid δ₁ receptor antagonist 7-benzylidenenaltrexone as an effective resistance reverser for chloroquine-resistant Plasmodium chabaudi.
AID235342Selectivity ratio against mu opioid receptor to that of delta opioid receptor1999Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3
The LMC delta opioid recognition pharmacophore: comparison of SNC80 and oxymorphindole.
AID229269Ratio of IC50 in presence of antagonist to that of control IC50 value in delta opioid receptor using DADLE ligand in mouse vas deferens1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (104)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's51 (49.04)18.2507
2000's37 (35.58)29.6817
2010's14 (13.46)24.3611
2020's2 (1.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.65 (24.57)
Research Supply Index4.64 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
Other103 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]